✦ LIBER ✦

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

✍ Scribed by Stephen R. D. Johnston, Henry Gómez, Salomon M. Stemmer, Maria Richie, Michael Durante, Lini Pandite, Vicki Goodman, Dennis Slamon

Book ID: 118796870
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 436 KB
Volume: 137
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-012-2399-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase II Trial of weekly pacl

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

✍ Giampietro Gasparini; Massimo Gion; Luigi Mariani; Paola Papaldo; Diana Crivella 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 222 KB

Randomized phase III trial of trastuzuma

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

3046 POSTER A randomized, open-label pha

3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer

✍ T.E. Ciuleanu; W. Scheithauer; G. Kurteva; J. Ocvirk; I. Koza; D. Papamichael; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

The combination of letrozole and trastuz

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

✍ P. Kelly Marcom; Claudine Isaacs; Lyndsay Harris; Zee Wang Wong; Aruna Kommarred 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 144 KB

Exemestane versus anastrozole as front-l

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

✍ Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Ant 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

Higher efficacy of letrozole in combinat

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

✍ J. Huober; P.A. Fasching; M. Barsoum; L. Petruzelka; D. Wallwiener; C. Thomssen; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 350 KB